ScholarLens Back to search
2001•TumoriRequires access

THE USE OF PCNA AND ANTI-CYTOKERATIN ANTIBODY (34βE12) IN THE DIFFERENTIAL DIAGNOSIS OF PROSTATE CANCER

Jie Zhang

Open publisher page 0 citations

Abstract

Objective To study the role of proliferating cell nuclear a nt igen PCNA and anti-cytokeratin antibody 34βE12 in the differential diagnosis o f prostate cancers. Methods 31 cases of prostate carcinoma and 20 cases of benign prostate hyperplasia were studied with immunohistochemical te chnique(SP). Results In 31 prostate cancers the average PCNA in dex was 0.55±0 23 and that in 20 cases of benign hyperplasia was 0.31±0 19 ( P 0 05). CK34βE12 expression was negative in all prostate cancers but i s positive in 19 out of 20 benign hyperplasia patients ( P 0 001). Conclusion PCNA expression is significantly higher in prostate cancer than in benign hyperplasia patients. CK34βE12 is negative in cancer pati ents but is 95% pasitive in benign hyperplasia patients. The combined detection of PCNA and CK34βE12 is very useful in the differential diagnosis of prostate diseases

About this research paper

What this paper is about

Objective To study the role of proliferating cell nuclear a nt igen PCNA and anti-cytokeratin antibody 34βE12 in the differential diagnosis o f prostate cancers. Methods 31 cases of prostate carcinoma and 20 cases of benign prostate hyperplasia were studied with immunohistochemical te chnique(SP). Results In 31 prostate cancers the average PCNA in dex was 0.55±0 23 and that in 20 cases of benign hyperplasia was 0.31±0 19 ( P 0 05). CK34βE12 expression was negative in all prostate cancers but i s positive in 19 out of 20 benign hyperplasia patients ( P 0 001). Conclusion PCNA expression is significantly higher in prostate cancer than in benign hyperplasia patients. CK34βE12 is negative in cancer pati ents but is 95% pasitive in benign hyperplasia patients. The combined detection of PCNA and CK34βE12 is very useful in the differential diagnosis of prostate diseases

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To study the role of proliferating cell nuclear a nt igen PCNA and anti-cytokeratin antibody 34βE12 in the differential diagnosis o f prostate cancers. Methods 31 cases of prostate carcinoma and 20 cases of benign prostate hyperplasia were studied with immunohistochemical te chnique(SP). Results In 31 prostate cancers the average PCNA in dex was 0.55±0 23 and that in 20 cases of benign hyperplasia was 0.31±0 19 ( P 0 05). CK34βE12 expression was negative in all prostate cancers but i s positive in 19 out of 20 benign hyperplasia patients ( P 0 001). Conclusion PCNA expression is significantly higher in prostate cancer than in benign hyperplasia patients. CK34βE12 is negative in cancer pati ents but is 95% pasitive in benign hyperplasia patients. The combined detection of PCNA and CK34βE12 is very useful in the differential diagnosis of prostate diseases

Key concepts: Hyperplasia, Proliferating cell nuclear antigen, Cytokeratin, Medicine, Prostate cancer, Prostate, Differential diagnosis, Immunohistochemistry

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
THE USE OF PCNA AND ANTI-CYTOKERATIN ANTIBODY (34βE12) IN THE DIFFERENTIAL DIAGNOSIS OF PROSTATE CANCER — Research Paper | ScholarLens